<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">2751</id>
  <title>T3D2709</title>
  <common-name>Phentermine</common-name>
  <description>Phentermine is only found in individuals that have used or taken this drug. It is a central nervous system stimulant and sympathomimetic with actions and uses similar to those of dextroamphetamine. It has been used most frequently in the treatment of obesity. Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse.Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.</description>
  <cas>122-09-8</cas>
  <pubchem-id>4771</pubchem-id>
  <chemical-formula>C10H15N</chemical-formula>
  <weight>149.120450</weight>
  <appearance>White powder.</appearance>
  <melting-point>205°C</melting-point>
  <boiling-point nil="true"/>
  <density nil="true"/>
  <solubility>18.6 g/L</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Phentermine is rapidly absorbed after oral ingestion.</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse.Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.</mechanism-of-toxicity>
  <metabolism>Hepatic.Half Life: 16 to 31 hours</metabolism>
  <toxicity>LD50: 15 to 20 mg/kg (monkey).</toxicity>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>For the treatment and management of obesity.</use-source>
  <min-risk-level nil="true"/>
  <health-effects>Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion.</health-effects>
  <symptoms>Symptoms of overdose include delirium, mania, self-injury, marked hypertension, tachycardia, arrhythmia, hyperpyrexia, convulsion, coma, and circulatory collapse.</symptoms>
  <treatment>Management of acute phentermine intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (REGITINE) has been suggested for possible acute, severe hypertension, if this complicates phentermine overdosage. (L1712)</treatment>
  <created-at type="dateTime">2009-07-21T20:26:15Z</created-at>
  <updated-at type="dateTime">2026-05-14T16:24:34Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Phentermine</wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id>C07438</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>8080</chebi-id>
  <biocyc-id>CPD-7657</biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id>Phentermine</stitch-id>
  <drugbank-id>DB00191</drugbank-id>
  <pdb-id></pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>CC(C)(N)CC1=CC=CC=C1</moldb-smiles>
  <moldb-formula>C10H15N</moldb-formula>
  <moldb-inchi>InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3</moldb-inchi>
  <moldb-inchikey>DHHVAGZRUROJKS-UHFFFAOYSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">149.2328</moldb-average-mass>
  <moldb-mono-mass type="decimal">149.120449485</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp>1.9</logp>
  <hmdb-id>HMDB14337</hmdb-id>
  <chembl-id>CHEMBL1574</chembl-id>
  <chemspider-id>4607</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference></synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM002141</chemdb-id>
  <dsstox-id>DTXSID9023461</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00008990</susdat-id>
  <iupac>2-methyl-1-phenylpropan-2-amine</iupac>
  <moldb-polar-surface-area>26.02</moldb-polar-surface-area>
  <moldb-refractivity>48.34340000000002</moldb-refractivity>
  <moldb-polarizability>17.874968045284582</moldb-polarizability>
  <moldb-rotatable-bond-count>2</moldb-rotatable-bond-count>
  <moldb-acceptor-count>1</moldb-acceptor-count>
  <moldb-donor-count>1</moldb-donor-count>
  <moldb-pka-strongest-acidic nil="true"/>
  <moldb-pka-strongest-basic>10.248513745149388</moldb-pka-strongest-basic>
  <moldb-physiological-charge>1</moldb-physiological-charge>
  <moldb-number-of-rings>1</moldb-number-of-rings>
  <moldb-alogps-logp>2.32</moldb-alogps-logp>
  <moldb-alogps-logs>-2.29</moldb-alogps-logs>
  <moldb-alogps-solubility>7.57e-01 g/l</moldb-alogps-solubility>
</compound>
